A Novel Hematological Inflammation-Nutrition Score (HINS) and Its Related Nomogram Model to Predict Survival Outcome in Advanced Gastric Cancer Patients Receiving First-Line Palliative Chemotherapy

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654–2664. doi:10.1016/S0140-6736(16)30354-3
   PubMed Web of Science ®Google Scholar
• Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised Phase 3 study. Lancet Oncol. 2009;10(11):1063–1069. doi:10.1016/S1470-2045(09)70259-1
   PubMed Web of Science ®Google Scholar
• Kang YK, Chin K, Chung HC, et al. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(8):1045–1056. doi:10.1016/S1470-2045(20)30315-6
   PubMed Web of Science ®Google Scholar
• Takahari D, Boku N, Mizusawa J, et al. Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. Oncologist. 2014;19(4):358–366. doi:10.1634/theoncologist.2013-0306
   PubMed Web of Science ®Google Scholar
• Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a Phase III trial. Lancet Oncol. 2008;9(3):215–221. doi:10.1016/S1470-2045(08)70035-4
   PubMed Web of Science ®Google Scholar
• Koizumi W, Takiuchi H, Yamada Y, et al. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Annal Oncol. 2010;21(5):1001–1005. doi:10.1093/annonc/mdp464
   PubMed Web of Science ®Google Scholar
• Takahari D, Mizusawa J, Koizumi W, Hyodo I, Boku N. Validation of the JCOG prognostic index in advanced gastric cancer using individual patient data from the SPIRITS and G-SOX trials. Gastric Cancer. 2017;20(5):757–763. doi:10.1007/s10120-017-0702-0
   PubMed Web of Science ®Google Scholar
• Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22(12):2395–2403. doi:10.1200/JCO.2004.08.154
   PubMed Web of Science ®Google Scholar
• McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12(3):223–226. doi:10.1097/MCO.0b013e32832a7902
   PubMed Web of Science ®Google Scholar
• Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218–230. doi:10.1016/j.critrevonc.2013.03.010
   PubMed Web of Science ®Google Scholar
• Leach M. Interpretation of the full blood count in systemic disease--A guide for the physician. J R Coll Physicians Edinb. 2014;44(1):36–41. doi:10.4997/JRCPE.2014.109
   PubMedGoogle Scholar
• Velioglu Y, Yuksel A. Complete blood count parameters in peripheral arterial disease. Aging Male. 2019;22(3):187–191. doi:10.1080/13685538.2019.1588873
   PubMed Web of Science ®Google Scholar
• Zinellu A, Paliogiannis P, Sotgiu E, et al. Blood cell count derived inflammation indexes in patients with idiopathic pulmonary fibrosis. Lung. 2020;198(5):821–827. doi:10.1007/s00408-020-00386-7
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–974. doi:10.1001/jama.280.11.969
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lu JJ, Du YP, Feng CX, Wang LQ, Chen MB. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer. Medicine. 2018;97(12):e0144. doi:10.1097/MD.0000000000010144
   PubMed Web of Science ®Google Scholar
• Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–6272. doi:10.3748/wjg.v23.i34.6261
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen B, Wang L, Wang R, Yang X. Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: a meta-analysis. Medicine. 2019;98(3):e13788. doi:10.1097/MD.0000000000013788
   Web of Science ®Google Scholar
• Zhang Y, Xiao G, Wang R. Clinical significance of systemic immune-inflammation index (SII) and C-reactive protein-to-albumin ratio (CAR) in patients with esophageal cancer: a meta-analysis. Cancer Manag Res. 2019;11:4185–4200. doi:10.2147/CMAR.S190006
   PubMed Web of Science ®Google Scholar
• Wang B, Huang Y, Lin T. Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma: a meta-analysis. Medicine. 2020;99(1):e18571. doi:10.1097/MD.0000000000018571
   PubMed Web of Science ®Google Scholar
• Qiu Y, Zhang Z, Chen Y. Prognostic value of pretreatment systemic immune-inflammation index in gastric cancer: a meta-analysis. Front Oncol. 2021;11:537140.
   PubMed Web of Science ®Google Scholar
• Huang L, Liu S, Lei Y, et al. Systemic immune-inflammation index, thymidine phosphorylase and survival of localized gastric cancer patients after curative resection. Oncotarget. 2016;7(28):44185–44193. doi:10.18632/oncotarget.9923
   PubMedGoogle Scholar
• Chen L, Yan Y, Zhu L, et al. Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy. Cancer Manag Res. 2017;9:849–867. doi:10.2147/CMAR.S151026
   PubMed Web of Science ®Google Scholar
• Guo J, Chen S, Chen Y, Li S, Xu D. Combination of CRP and NLR: a better predictor of postoperative survival in patients with gastric cancer. Cancer Manag Res. 2018;10:315–321. doi:10.2147/CMAR.S156071
   PubMed Web of Science ®Google Scholar
• Yılmaz A, Mirili C, Tekin SB, Bilici M. The ratio of hemoglobin to red cell distribution width predicts survival in patients with gastric cancer treated by neoadjuvant FLOT: a retrospective study. Ir J Med Sci. 2020;189(1):91–102. doi:10.1007/s11845-019-02153-x
   PubMed Web of Science ®Google Scholar
• Alwarawrah Y, Kiernan K, MacIver NJ. Changes in nutritional status impact immune cell metabolism and function. Front Immunol. 2018;9:1055. doi:10.3389/fimmu.2018.01055
   PubMed Web of Science ®Google Scholar
• Lu J, Xu BB, Zheng ZF, et al. CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized phase III trial. Gastric Cancer. 2019;22(3):536–545. doi:10.1007/s10120-018-0892-0
   PubMed Web of Science ®Google Scholar
• Seebacher V, Grimm C, Reinthaller A, et al. The value of serum albumin as a novel independent marker for prognosis in patients with endometrial cancer. Eur J Obstet Gynecol Reprod Biol. 2013;171(1):101–106. doi:10.1016/j.ejogrb.2013.07.044
   PubMed Web of Science ®Google Scholar
• Wei C, Yu Z, Wang G, Zhou Y, Tian L. Low pretreatment albumin-to-globulin ratio predicts poor prognosis in gastric cancer: insight from a meta-analysis. Front Oncol. 2020;10:623046. doi:10.3389/fonc.2020.623046
   PubMed Web of Science ®Google Scholar
• Guner A, Cho M, Kim YM, Cheong JH, Hyung WJ, Kim HI. Prognostic value of postoperative neutrophil and albumin: reassessment one month after gastric cancer surgery. Front Oncol. 2021;11:633924. doi:10.3389/fonc.2021.633924
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Okabayashi K, Hasegawa H, et al. Comparison of preoperative inflammation-based prognostic scores in patients with colorectal cancer. Ann Surg. 2018;267(3):527–531. doi:10.1097/SLA.0000000000002115
   PubMed Web of Science ®Google Scholar
• Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–1235. doi:10.1016/S1470-2045(14)70420-6
   PubMed Web of Science ®Google Scholar
• Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–2471. doi:10.1016/S0140-6736(17)31827-5
   PubMed Web of Science ®Google Scholar
• Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437–1448. doi:10.1016/S1470-2045(18)30739-3
   PubMed Web of Science ®Google Scholar
• Carter GC, Kaltenboeck A, Ivanova J, et al. Real-world treatment patterns among patients with advanced gastric cancer in South Korea. Cancer Res Treat. 2017;49(3):578–587. doi:10.4143/crt.2016.001
   PubMed Web of Science ®Google Scholar
• Duan RD, Nilsson A. Metabolism of sphingolipids in the gut and its relation to inflammation and cancer development. Prog Lipid Res. 2009;48(1):62–72. doi:10.1016/j.plipres.2008.04.003
   PubMed Web of Science ®Google Scholar
• Maletzki C, Emmrich J. Inflammation and immunity in the tumor environment. Digest Dis. 2010;28(4–5):574–578. doi:10.1159/000321062
   PubMed Web of Science ®Google Scholar
• Lian L, Xia YY, Zhou C, et al. Application of platelet/lymphocyte and neutrophil/lymphocyte ratios in early diagnosis and prognostic prediction in patients with resectable gastric cancer. Cancer Biomark. 2015;15(6):899–907. doi:10.3233/CBM-150534
   PubMed Web of Science ®Google Scholar
• Hsu JT, Wang CC, Le PH, et al. Lymphocyte-to-monocyte ratios predict gastric cancer surgical outcomes. J Surg Res. 2016;202(2):284–290. doi:10.1016/j.jss.2016.01.005
   PubMed Web of Science ®Google Scholar
• Wang SC, Chou JF, Strong VE, Brennan MF, Capanu M, Coit DG. Pretreatment neutrophil to lymphocyte ratio independently predicts disease-specific survival in resectable gastroesophageal junction and gastric adenocarcinoma. Ann Surg. 2016;263(2):292–297. doi:10.1097/SLA.0000000000001189
   PubMed Web of Science ®Google Scholar
• Bilen MA, Martini DJ, Liu Y, et al. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer. 2019;125(1):127–134. doi:10.1002/cncr.31778
   PubMed Web of Science ®Google Scholar
• Zhang X, Hu D, Lin X, et al. Prognostic value of an inflammation-related index in 6865 Chinese patients with postoperative digestive tract cancers: the FIESTA study. Front Oncol. 2019;9:427. doi:10.3389/fonc.2019.00427
   PubMed Web of Science ®Google Scholar
• Li Z, Li S, Ying X, et al. The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy. Gastric Cancer. 2020;23(3):540–549. doi:10.1007/s10120-019-01027-6
   PubMed Web of Science ®Google Scholar
• He K, Si L, Pan X, et al. Preoperative Systemic Immune-Inflammation Index (SII) as a superior predictor of long-term survival outcome in patients with stage I-II gastric cancer after radical surgery. Front Oncol. 2022;12:829689. doi:10.3389/fonc.2022.829689
   PubMed Web of Science ®Google Scholar
• Park SH, Lee S, Song JH, et al. Prognostic significance of body mass index and prognostic nutritional index in stage II/III gastric cancer. Eur J Surg Oncol. 2020;46(4 Pt A):620–625. doi:10.1016/j.ejso.2019.10.024
   PubMed Web of Science ®Google Scholar
• Xishan Z, Ye Z, Feiyan M, Liang X, Shikai W. The role of prognostic nutritional index for clinical outcomes of gastric cancer after total gastrectomy. Sci Rep. 2020;10(1):17373. doi:10.1038/s41598-020-74525-8
   PubMed Web of Science ®Google Scholar
• Nozoe T, Iguchi T, Egashira A, Adachi E, Matsukuma A, Ezaki T. Significance of modified Glasgow prognostic score as a useful indicator for prognosis of patients with gastric carcinoma. Am J Surg. 2011;201(2):186–191. doi:10.1016/j.amjsurg.2010.01.030
   PubMed Web of Science ®Google Scholar
• Banna GL, Friedlaender A, Tagliamento M, et al. Biological rationale for peripheral blood cell-derived inflammatory indices and related prognostic scores in patients with advanced non-small-cell lung cancer. Curr Oncol Rep. 2022;24(12):1851–1862. doi:10.1007/s11912-022-01335-8
   PubMed Web of Science ®Google Scholar
• Hacker UT, Hasenclever D, Baber R, et al. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial. Annal Oncol. 2022;33(7):685–692. doi:10.1016/j.annonc.2022.03.274
   PubMed Web of Science ®Google Scholar
• Kinoshita A, Onoda H, Imai N, et al. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer. 2012;107(6):988–993. doi:10.1038/bjc.2012.354
   PubMed Web of Science ®Google Scholar
• Kuroda D, Sawayama H, Kurashige J, et al. Controlling Nutritional Status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection. Gastric Cancer. 2018;21(2):204–212. doi:10.1007/s10120-017-0744-3
   PubMed Web of Science ®Google Scholar
• Liu BZ, Tao L, Chen YZ, et al. Preoperative body mass index, blood albumin and triglycerides predict survival for patients with gastric cancer. PLoS One. 2016;11(6):e0157401. doi:10.1371/journal.pone.0157401
   PubMed Web of Science ®Google Scholar
• Yin X, Fang T, Wang Y, et al. Prognostic significance of serum inflammation indexes in different Lauren classification of gastric cancer. Cancer Med. 2021;10(3):1103–1119. doi:10.1002/cam4.3706
   PubMed Web of Science ®Google Scholar
• Shimozaki K, Nakayama I, Takahari D, et al. A novel clinical prognostic index for patients with advanced gastric cancer: possible contribution to the continuum of care. ESMO open. 2021;6(5):100234. doi:10.1016/j.esmoop.2021.100234
   PubMed Web of Science ®Google Scholar
• Chon HJ, Hyung WJ, Kim C, et al. Differential prognostic implications of gastric signet ring cell carcinoma: stage adjusted analysis from a single high-volume center in Asia. Ann Surg. 2017;265(5):946–953. doi:10.1097/SLA.0000000000001793
   PubMed Web of Science ®Google Scholar
• Yan HHN, Siu HC, Law S, et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell. 2018;23(6):882–897.e811. doi:10.1016/j.stem.2018.09.016
   PubMed Web of Science ®Google Scholar
• Graesslin O, Abdulkarim BS, Coutant C, et al. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol. 2010;28(12):2032–2037. doi:10.1200/JCO.2009.24.6314
   PubMed Web of Science ®Google Scholar
• Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev. 2014;33(1):231–269. doi:10.1007/s10555-014-9498-0
   PubMed Web of Science ®Google Scholar
• Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M. The platelet-cancer loop. Eur J Intern Med. 2013;24(5):393–400. doi:10.1016/j.ejim.2013.01.017
   PubMed Web of Science ®Google Scholar
• Gao QF, Qiu JC, Huang XH, et al. The predictive and prognostic role of a novel ADS score in esophageal squamous cell carcinoma patients undergoing esophagectomy. Cancer Cell Int. 2018;18:153. doi:10.1186/s12935-018-0648-2
   PubMed Web of Science ®Google Scholar
• Petrie HT, Klassen LW, Kay HD. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol. 1985;134(1):230–234. doi:10.4049/jimmunol.134.1.230
   PubMed Web of Science ®Google Scholar
• Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci. 2007;98(11):1652–1658. doi:10.1111/j.1349-7006.2007.00606.x
   PubMed Web of Science ®Google Scholar
• Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016;16(7):431–446. doi:10.1038/nrc.2016.52
   PubMed Web of Science ®Google Scholar
• Cools-Lartigue J, Spicer J, McDonald B, et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013;123(8):3446–3458. doi:10.1172/JCI67484
   PubMed Web of Science ®Google Scholar
• Najmeh S, Cools-Lartigue J, Rayes RF, et al. Neutrophil extracellular traps sequester circulating tumor cells via β1-integrin mediated interactions. Inter J Cancer. 2017;140(10):2321–2330. doi:10.1002/ijc.30635
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137–148. doi:10.1016/j.immuni.2004.07.017
   PubMed Web of Science ®Google Scholar
• Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30(21):2678–2683. doi:10.1200/JCO.2011.37.8539
   PubMed Web of Science ®Google Scholar
• Santoiemma PP, Powell DJ Jr. Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther. 2015;16(6):807–820. doi:10.1080/15384047.2015.1040960
   PubMed Web of Science ®Google Scholar
• Fogar P, Sperti C, Basso D, et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas. 2006;32(1):22–28. doi:10.1097/01.mpa.0000188305.90290.50
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69(13):5383–5391. doi:10.1158/0008-5472.CAN-08-3845
   PubMed Web of Science ®Google Scholar
• Carvalho JR, Verdelho Machado M. New insights about albumin and liver disease. Ann Hepatol. 2018;17(4):547–560. doi:10.5604/01.3001.0012.0916
   PubMed Web of Science ®Google Scholar
• Gounden V, Vashisht R, Jialal I. Hypoalbuminemia. In: Disclosure: Rishik Vashisht Declares No Relevant Financial Relationships with Ineligible Companies. Disclosure: Ishwarlal Jialal Declares No Relevant Financial Relationships with Ineligible Companies. Treasure Island (FL) Ineligible Companies: StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC; 2023.
   Google Scholar
• Hirahara N, Tajima Y, Fujii Y, et al. Prognostic nutritional index as a predictor of survival in resectable gastric cancer patients with normal preoperative serum carcinoembryonic antigen levels: a propensity score matching analysis. BMC Cancer. 2018;18(1):285. doi:10.1186/s12885-018-4201-4
   PubMed Web of Science ®Google Scholar
• Jiang P, Jia M, Hu J, Huang Z, Deng Y, Hu Z. A nomogram model involving immunohistochemical markers for predicting the recurrence of stage I-II endometrial cancer. Front Oncol. 2020;10:586081. doi:10.3389/fonc.2020.586081
   PubMed Web of Science ®Google Scholar